ARS Pharmaceuticals Inc’s recent filing unveils that its Chief Commercial Officer Karas Eric unloaded Company’s shares for reported $0.25 million on Jul 01 ’25. In the deal valued at $16.99 per share,15,000 shares were sold. As a result of this transaction, Karas Eric now holds 10,315 shares worth roughly $0.18 million.
Then, Flynn James E sold 740,149 shares, generating $13,663,151 in total proceeds. Upon selling the shares at $18.46, the 10% Owner now owns 4,887,254 shares.
Before that, ERIC KARAS bought 15,000 shares. ARS Pharmaceuticals Inc shares valued at $254,859 were divested by the Officer at a price of $16.99 per share.
Scotiabank initiated its ARS Pharmaceuticals Inc [SPRY] rating to a Sector outperform in a research note published on March 07, 2025; the price target was $30. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early February with a ‘”an Outperform”‘ rating. Cantor Fitzgerald began covering SPRY with “an Overweight” recommendation on August 20, 2024. Raymond James revised its rating on August 13, 2024. It rated SPRY as “a Strong buy” which previously was an “an Outperform”.
Price Performance Review of SPRY
On Monday, ARS Pharmaceuticals Inc [NASDAQ:SPRY] saw its stock jump 3.45% to $17.09. Over the last five days, the stock has lost -6.10%. ARS Pharmaceuticals Inc shares have risen nearly 97.34% since the year began. Nevertheless, the stocks have risen 61.99% over the past one year. While a 52-week high of $18.90 was reached on 06/27/25, a 52-week low of $8.85 was recorded on 03/04/25.
Levels Of Support And Resistance For SPRY Stock
The 24-hour chart illustrates a support level at 16.39, which if violated will result in even more drops to 15.68. On the upside, there is a resistance level at 17.85. A further resistance level may holdings at 18.60.
How much short interest is there in ARS Pharmaceuticals Inc?
A steep rise in short interest was recorded in ARS Pharmaceuticals Inc stocks on 2025-06-13, dropping by -1.65 million shares to a total of 16.58 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 18.23 million shares. There was a decline of -9.98%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 12, 2024 when Leerink Partners resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $20.
